An investigational antibody-drug conjugate targeting two growth-driving proteins in lung cancer reached a recommended Phase 3 dose in EGFR-mutated disease after resistance to targeted therapy, according to data presented at the 2026 World Conference on Lung Cancer in Seoul. The update specifically addresses patients whose tumors had progressed on modern EGFR-directed treatments. The move toward a Phase 3 dose supports progression of ADC development in a setting where post-targeted-therapy options are limited and resistance biology is heterogeneous. For developers, it also signals that the ADC’s therapeutic window is being refined for registrational trial design. For the broader industry, the ADC reinforces continued clinical investment in dual-target constructs aimed at improving efficacy after targeted therapy failure.